ClinicalTrials.gg
CompletedNCT06435442Updated Apr 16, 2026

PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers

A Phase 1 interventional study of Epaminurad, Naproxen and Epaminurad in Healthy, sponsored by JW Pharmaceutical. Completed at 1 site in South Korea. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by JW Pharmaceutical · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Study summary

A Phase 1 Study to evaluate the safety, PK/PD, drug-drug interaction(DDI) of Epaminurad and Naproxen in Healthy Volunteers

Read the detailed description

Part 1: to evaluate the safety, PK/PD, drug-drug interaction(DDI) of Epaminurad and Naproxen in Healthy Koreans/ Part 2: to evaluate the safety, PK/PD of Epaminurad in Healthy Caucasians

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

JW Pharmaceutical is the lead sponsor of 77 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 19\~50
  2. Weight: between 50.0 kg\~90.0 kg, (BMI): 18.0 kg/m\^2 or heavier and below 30.0 kg/m\^2
  3. Part 1: Korean/ Part 2: Caucasian

Exclusion criteria

Exclusion Criteria:

  1. Medical history- chronic liver disease, acute gout attack, uric acid stone, diabetes, hypertension, hyperlipidemia or lipid abnormality
  2. Clinical examination- (CKD-EPI) \< 90mL/min/1.73m\^2, Serum uric acid \< 3 mg/dL or > 7 mg/dL, (SGOT), ALT (SGPT) > ranges X 1.5, Total , γ-GTP > upper limit of normal ranges X 1.5, CK > upper limit of normal ranges X 2, Positive serologic results Cystatin C > 1.26mg/L (man), > 1.19 mg/L (woman)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Part 1

    Epaminurad 6 mg, Epaminurad 9 mg, Naproxen 500 mg

    Drug: Epaminurad, Naproxen

  • Experimental
    Part 2(Test group)

    Epaminurad 6 mg, Epaminurad 9 mg

    Drug: Epaminurad

  • Placebo comparator
    Part 2(Control group)

    Epaminurad 6 mg placebo, Epaminurad 9 mg placebo

    Drug: Epaminurad placebo

Interventions

  • DrugEpaminurad, Naproxen

    Drug pages: Epaminurad · Naproxen

    Period 1: Epaminurad 6mg -\> Epaminurad 9mg -\> Epaminurad 9mg +Naproxen Period 2: Naproxen

    Also known as: URC102, Naxen

  • Epaminurad

    Also known as: URC102

  • DrugEpaminurad placebo

    Epaminurad placebo

    Also known as: URC102 placebo

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration versus time curve (AUC)

    To evaluate the AUC of Naproxen

    Time frame: 5 days

  2. Area under the plasma concentration versus time curve (AUC)

    To evaluate the AUC of Epaminurad

    Time frame: 7 days

  3. Peak plasma concentrations (Cmax)

    To evaluate the Cmax of Epaminurad

    Time frame: 7 days

  4. Peak plasma concentrations (Cmax)

    To evaluate the Cmax of Naproxen

    Time frame: 5 days

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Dec 2025, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2024
First posted
May 30, 2024
StartActual
Jun 3, 2024
Primary completionActual
Dec 30, 2025
CompletionActual
Dec 30, 2025
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06435442
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
May 30, 2024
Start date
Jun 3, 2024
Primary completion
Dec 30, 2025
Completion
Dec 30, 2025
Last update
Apr 16, 2026

Study contacts

Kyung-sang Yu, MD
principal investigator · Seoul National University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Epaminurad · Naproxen

Start the discussion